Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
ConclusionsLenvatinib was cost-effective compared with sorafenib for the first-line treatment of uHCC in Japan.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Gastroenterology | Hepatocellular Carcinoma | Japan Health | Liver Cancer | Statistics | Study